参考文献/References:
[1] Calinescu AA, Kamran N, Baker G, et al. Overview of cu-
rrent immunotherapeutic strategies for glioma [J]. Immuno-
therapy, 2015, 7(10): 1073-1104.
[2] Wong AJ, Ruppert JM, Bigner SH, et al. Structural altera-
tions of the epidermal growth factor receptor gene in human
gliomas [J]. Proc Natl Acad Sci USA, 1992, 89(7): 2965-
2969.
[3] Antonyak M, AMoscatello DK, Wong AJ. Constitutive acti-
vation of c-Jun N-terminal kinase by a mutant epidermal
growth factor receptor [J]. J Biol Chem, 1998, 273(5):
2817-2822.
[4] Sampson JH, Archer GE, Mitchell DA, et al. An epidermal
growth factor receptor variant Ⅲ-targeted vaccine is safe
and immunogenic in patients with glioblastoma multiforme
[J]. Mol Cancer Ther, 2009, 8(10): 2773-2779.
[5] Heimberger AB, Bhussain SF, Aldape K, et al. Tumor-
specific peptide vaccination in newly-diagnosed patients
with GBM [J]. J Clin Oncol, 2006, 24 (18 Suppl): 2529.
[6] Liau LMP, Rins RM, Kiertscher SME, et al. Dendritic cell
vaccination in glioblastoma patients induces systemic and
intracranial T-cell responses modulated by the local central
nervous system tumor microenvironment [J]. Clin Cancer
Res, 2005, 11(15): 5515-5525.
[7] Dutoit V, Herold-Mende C, Hilf N, et al. Exploiting the
glioblastoma peptidome to discover novel tumour-associated
antigens for immunotherapy [J]. Brain, 2012, 135(4): 1042-
1054.
[8] Phillips HSK, harbanda S, Chen R, et al. Molecular sub-
classes of high-grade glioma predict prognosis, delineate a
pattern of disease progression, and resemble stages in
neurogenesis [J]. Cancer Cell, 2006, 9(3): 157-173.
[9] Saikali S, Avril T, Collet B, et al. Expression of nine tumour
antigens in a series of human glioblastoma multiforme:
interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for
immunotherapy [J]. J Neurooncol, 2007, 81(2): 139-148.
[10] Liu G, Ying HZ, eng G, et al. HER-2, gp100 and MAGE-1
are expressed in human glioblastoma and recognized by
cytotoxic T cells [J]. Cancer Res, 2004, 64(14): 4980-4986.
[11] Carter T, Shaw H, Cohn-Brown D, et al. Ipilimumab and
Bevacizumab in Glioblastoma [J]. Clin Oncol(R Coll Radiol),
2016, 28(10): 622-626.
[12] Salmggi A, Eoli MF, rigerio S, et al. Intracavitary VEGF,
bFGF, IL-8, IL-12 levels in primary and recurrent malig-
nant glioma [J]. Neurooncol, 2003, 62(3): 297-303.
[13] Ferrars N. Vascular endothelial growth factor: basic science
and clinical progress [J]. Endocr Rev, 2004, 25(4): 581-
611.
[14] Friedman HSP, radoa MD, Wen PY, et al. Bevacizumab
alone and in combination with irinotecan in recurrent
glioblastoma [J]. J Clin Oncol, 2009, 27(28): 4733-4740.
[15] Kreisl TN, KimL, Moore K, et al. Phase 2 trial of single-
agent bevacizumab followed by bevacizumab plus irinotocan
at tumor progress in recurrent glioblastoma [J]. J Clin Oncol,
2009, 27(5): 740-745.
[16] Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation
improves expansion and persistence of chimeric antigen
receptor-modified T cells in lymphoma patients [J]. Clin
Invast, 2011, 121(6): 1822-1826.
[17] Choi BD, Suryadevara CM, Gedeon PC, et al. Intracerebral
delivery of a third generation EGFRvⅢ-specific chimeric
antigen receptor is efficacious against human glioma [J].
Clin Neurosci, 2014, 21: 189-190.
[18] Sampson JH, Choi BDS, anchez-Perez L, et al. EGFRvⅢ
mCAR-modified T cell therapy cures mice with established
intracerebral glioma and generates host immunity against
tumor-antigen loss [J]. Clin Cancer Res, 2014, 20: 972-
984.